-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Suzhou, China, Cambridge, Massachusetts, and Rotterdam, the Netherlands, October 19, 2021/PRNewswire/ - Hebo Pharmaceutical (stock code: 02142.
HK) recently announced its fully human anti-FcRn antibody Bartoli The phase II clinical trial of monoclonal antibody (HBM9161) for thyroid eye disease has completed the first administration of the first subject
.
This clinical trial aims to evaluate the efficacy and safety of bartolizumab (HBM9161) in the treatment of thyroid ophthalmopathy in China
Hebo Medicine is committed to building bartolizumab (HBM9161) into a series of product pipelines to treat a variety of autoimmune diseases mediated by pathogenic IgG to meet the current huge medical needs.
Thyroid eye disease is One of the first indications for this drug candidate to be studied
.
Dr.
Chen Xiaoxiang, Chief Product Development Officer of Hebo Medicine, said: “Thyroid ophthalmopathy is a disease that seriously affects the quality of life of patients.
The current treatment methods are very limited, mainly relying on high-dose hormones, with limited efficacy and serious side effects, especially for exophthalmos and exophthalmos.
Clinical problems such as strabismus that can cause long-term serious consequences are not satisfactory.
The clinical research of bartolizumab, which directly targets the pathogenesis of thyroid ophthalmopathy, has brought new hope for the treatment of the disease
.
"
About Bartolizumab (HBM9161)
Bartolizumab (HBM9161) is a fully human monoclonal antibody (mAb) that can block the binding of FcRn-IgG to each other, accelerate the elimination of IgG in the body, and achieve effective treatment of pathogenic IgG-mediated autoimmunity The effect of the disease
.
In the phase II study of myasthenia gravis, bartolizumab can quickly and significantly relieve clinical symptoms and improve the quality of life of patients
About Thyroid Eye Disease (TED)
Thyroid ophthalmopathy (also known as Graves' ophthalmopathy (GO), or thyroid-associated ophthalmopathy (TAO)) is the most common extra-thyroid manifestation of Graves' disease (GD) and can also be seen in chronic autoimmune thyroiditis
.
Clinical manifestations include eyelid swelling and redness, conjunctival congestion and edema, eyelid retraction, exophthalmos (protruding eyes), and eye movement disorders and diplopia
For moderate to severe patients during the active phase, intravenous high-dose corticosteroids are the main treatment option, but the effect of hormones on exophthalmos and strabismus is not ideal, and the side effects are obvious
.
Rituximab, tocilizumab, etc.
About Hebo Pharmaceutical
Hebo Pharmaceutical (stock code: 02142.
HK) is a global biopharmaceutical company focusing on the research and development and commercialization of innovative drugs in the field of tumors and immune diseases
.
The company rapidly expands its innovative drug research and development pipeline through independent research and development, joint development and diversified cooperation models
Harbour Mice®, Hebo's own antibody technology platform, can generate fully human monoclonal antibodies in dual, dual light chain (H2L2) and heavy chain only (HCAb) forms
.
The immune cell adapter (HBICE®) developed based on the HCAb antibody platform can achieve anti-tumor effects that cannot be achieved by traditional drug combination therapy
